CLEVELAND, Sept. 25, 2017 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today the launch of a multi-center
prospective clinical trial for locally advanced unresectable
pancreatic cancer using MRIdian, the world's first and only
FDA-cleared MRI-guided radiation therapy system. This study is the
first initiative of ViewRay's Clinical Cooperative Think Tank
(C2T2), a group of MRIdian clinical users
focused on evidence gathering to support MR-guided radiation
therapy.
At the inaugural meeting of the C2T2 on
September 23, 2017, participants
formalized the group's first key initiative – a multi-center,
prospective, single-arm clinical trial focused on locally advanced
unresectable pancreatic cancer. Pancreatic cancer presents
considerable radiation targeting challenges given the known
limitations of conventional CT image guidance. The novel abilities
provided by live MR guidance combined with daily online treatment
adaptation have potentially enabled a new approach in pancreatic
cancer therapy. Through this trial the group looks to explore new
opportunities to improve survival and quality of life for this
deadly disease.
One particular impetus for the trial was compelling early
results presented as part of the scientific sessions at the
American Society for Radiation Oncology (ASTRO) annual meeting. The
poster, titled "Higher Maximum Biologic Effective Dose Utilizing
Adaptive MRI Guided Radiation Therapy Improves Survival of
Inoperable Pancreatic Cancer Patients", provided a retrospective
review of 42 locally-advanced pancreatic cancer patients treated at
four institutions (Washington
University, UCLA, University of Wisconsin, and VUmc). The study found
that stereotactic dosing regimens guided by MR imaging and daily
online adaptation had led to significantly prolonged patient
survival and resulted in favorably low toxicity.
"Based on compelling early evidence on the use of MRIdian to
treat locally advanced pancreatic cancer, we are eager to further
explore the system's capabilities and associated toxicity, local
control and patient outcomes," said Parag
Parikh, M.D., Associate Professor of Radiation Oncology at
Washington University and lead
investigator of the trial. "We believe MRIdian's excellent
real-time visualization of organs at risk within the abdomen and
its daily treatment adaptation will allow us to deliver higher,
more effective doses to the target while minimizing impact on the
normal surrounding tissue. The findings of this study could truly
change the standard of care for many pancreatic cancer
patients."
A video of Dr. Parikh discussing the multi-institutional poster
in ViewRay's ASTRO booth is available on the company's website at
http://www.viewray.com/ASTRO_2017.
As part of ASTRO's Scientific Sessions, an additional
presentation of pancreatic cancer outcomes from UCLA will be delivered. The presentation titled,
"Outcomes Utilizing MRI-guided and Real-Time Adaptive Pancreas
Stereotactic Body Radiotherapy (SBRT)" will be given on
Wednesday, September 27 at
2:40 p.m. PT in room 30 D/E.
ViewRay's C2T2, the consortium initiating
the trial, comprises clinicians from leading institutions around
the world including:
- Dana-Farber/Brigham and
Women's Cancer Center in Boston
- Henry Ford Cancer Institute, Detroit
- Institut du Cancer de Montpellier, France
- Institut Paoli Calmettes, Marseille,
France
- Loyola Center for Cancer Care and Research at Palos Health
South Campus in Illinois
- Moffitt Cancer Center in Tampa,
Florida
- Miami Cancer Institute, Baptist Health South Florida
- National Cancer Center (NCC) in Tokyo, Japan
- Orlando Health UF Health Cancer Center
- Policlinico Agostino Gemelli, Universita Cattolica del Sacro
Cuore, Gemelli ART in Rome,
Italy
- Seoul National University Hospital
(SNUH) in Seoul, South Korea
- Sylvester Comprehensive Cancer Center, UHealth - University of Miami Health System
- University of California, Los
Angeles Health System and Jonsson Comprehensive Cancer
Center
- University of Wisconsin Carbone
Cancer Center in Madison
- VU University Medical Center in Amsterdam, Netherlands
- Washington University and Siteman
Cancer Center at Barnes-Jewish Hospital, St. Louis
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian integrates MRI
technology, radiation delivery and proprietary software to locate,
target and track the position and shape of soft-tissue tumors
during radiation. ViewRay believes this combination of enhanced
visualization and accuracy will significantly improve outcomes for
patients.
ViewRay and MRIdian are registered trademarks of ViewRay,
Inc.
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to clinical trial plans and
presentations featured at ASTRO, and statements made in the video
and poster referenced in this release. Actual results could differ
from those projected in any forward-looking statements due to
numerous factors. Such statements are subject to risks and
uncertainties that could cause future results to differ materially
from those referenced. Additional factors include, among others,
the ability to raise the additional funding needed to continue to
pursue ViewRay's business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, competition in the industry in which ViewRay operates
and overall market conditions. These forward-looking statements are
made as of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
Investors should consult all of the information set forth herein
and should also refer to the risk factor disclosure set forth in
the reports and other documents ViewRay files with the SEC
available at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/viewray-launches-clinical-trial-following-compelling-early-pancreatic-cancer-data-with-mridian-system-300524824.html
SOURCE ViewRay, Inc.